I'll research IVZ (Invesco) before writing the preview. Let me gather recent earnings, filings, news, and stock price data.Let me read the most recent quarter's earnings materials and check recent news/AUM data.Let me get recent news context and check for monthly AUM updates and the QQQ competitive situation.Let me read the June AUM release (most recent, going into Q2 earnings) and check for the Q2 earnings announcement details.Let me check analyst consensus estimates and the QQQ competitive backdrop via web search, plus peer/macro context.Web search has no data for this period. Let me pull the prior-year Q2 2025 release for year-over-year comparison anchors.I now have everything I need. Let me verify a couple of computed figures before writing.Here is the earnings preview.
IVZ heads into Q2 with the wind at its back: a sharp equity-market recovery drove average AUM up ~7% sequentially, this is the first full quarter in which the newly converted QQQ contributes management fees, and the flow engine (11 straight quarters of net inflows) keeps humming. The bar this quarter is less about "will the numbers be good" — the AUM tailwind makes strong revenue/margin comps close to mechanical — and more about the durability of QQQ economics amid new competition, the sustainability of organic growth, and whether operating margin can keep climbing toward the high-30s.
Invesco's monthly disclosures already tell most of the Q2 story. Ending AUM marched steadily higher through the quarter as markets rebounded from the early-year selloff:
| Month-end | Total AUM ($B) | QQQ ($B) | ETFs & Index ($B) | China JV ($B) |
|---|---|---|---|---|
| Mar 31, 2026 (Q1 end) | 2,159.5 | 372.5 | 638.3 | 141.9 |
| Apr 30, 2026 | 2,339.4 | 440.3 | 701.4 | 154.3 |
| May 31, 2026 | 2,453.9 | 494.0 | 745.8 | 158.7 |
| Jun 30, 2026 (Q2 end, prelim) | 2,470.3 | 490.1 | 753.5 | 163.2 |
Key takeaways: - Ending AUM ~$2.47T is a record, up ~14% from Q1's $2,159.5B. - Preliminary average total AUM for Q2 was $2,368.8B — up ~6.8% vs. Q1's $2,218.9B and ~24.8% vs. Q2-25's $1,897.4B. Average AUM (not ending) drives fee revenue, so this is the number that matters, and it is unambiguously a tailwind. - QQQ rebounded from $372.5B to ~$490B. Recall QQQ swung to net outflows in Q1 (–$10.8B, "normal rotation and profit-taking"), but management said on the Q1 call that inflows and demand "returned" in April as volatility abated. The June figure confirms a strong recovery. - China JV kept compounding — from $141.9B to $163.2B — continuing the standout 30%+ annualized organic growth story. - June alone produced +$8.0B of net long-term inflows plus +$14.3B money-market inflows, so the quarter almost certainly extended the 11-quarter positive-organic-growth streak to 12.
Two structural items make the headline YoY comparison look explosive and require adjustment when judging the "true" beat/miss:
Recent quarterly track record (adjusted):
| Q2-25 | Q3-25 | Q4-25 | Q1-26 | |
|---|---|---|---|---|
| Net revenues ($M) | 1,104.6 | — | 1,258.9 | 1,264.3 |
| Adj. operating margin | 31.2% | — | 36.4% | 34.5% |
| Adj. diluted EPS | $0.36 | — | $0.62 | $0.57 |
Holding the Q1 net revenue yield (~5.7 bps/quarter, ~22.8 bps annualized — which management said is stabilizing/inflecting) flat against Q2 average AUM of $2,368.8B implies net revenue of roughly ~$1.35B, up ~7% sequentially and ~22% YoY. With adjusted operating expenses guided to a ~$3.275B annual run-rate (~$815–820M/quarter) and Q1's elevated seasonal comp items rolling off (the $33M accelerated retirement-award expense and ~$15M of seasonal payroll taxes), adjusted operating income should step up meaningfully — plausibly ~$510–540M, pushing adjusted operating margin toward ~37–39% from Q1's 34.5%. That maps to adjusted EPS in roughly the ~$0.65–0.70 zone (vs. $0.57 in Q1 and $0.36 in Q2-25).
Treat these as my directional estimates, not consensus — I couldn't retrieve a reliable Street number. The point is that the setup skews toward strong sequential and YoY operating leverage; the risk is more in tone/guidance and in QQQ competitive commentary than in the printed quarter.
Modeling housekeeping: management guided Q2 GAAP effective tax rate to 25–26% (adjusted was 23.6% in Q1); watch pass-through mechanics (third-party + distribution fees / management fees expected in the 22–23% range with full QQQ impact).
a) QQQ competitive moat — the marquee issue. NASDAQ has expanded licensing to allow additional U.S.-listed Nasdaq-100 ETFs. Management pushed back hard in Q1: any competitor pays the same 8 bp index-licensing fee; QQQ's edge is 25+ years of brand, unmatched liquidity/tight spreads, deep options markets, and high tax-driven switching costs on an entrenched installed base (they cite that QQQM expanded the ecosystem without cannibalizing QQQ). With QQQ now a core fee driver (~$490B), any evidence on flow retention, fee posture, and the international QQQ rollout (Japan launching this year, after Hong Kong) will move the stock. The broader QQQ "innovation suite" is ~$550B globally.
b) Organic growth breadth & mix. Q1 delivered $21.8B net LT inflows (4.4% annualized) with strength across ETFs (+$18.6B), China JV (+$8.7B), fundamental fixed income (+$3.7B), and multi-asset, plus record active inflows (~$15B) and moderating fundamental-equity outflows (–$2.4B, the smallest in ~9 years). Watch whether APAC (17% annualized) and EMEA (8%) momentum and institutional demand (5+ consecutive quarters >5% organic) persist, and whether fundamental equities can approach flat.
c) Margin trajectory & the expense guide. Management reiterated a path from mid-30s toward high-30s margins. Cross-check Q2 against the $3.275B FY26 adjusted-opex framework, comp as a % of net revenue (targeting ~mid-point of the 38–42% range), the hybrid-investment-platform implementation costs ($10–15M/quarter through 2026) and the promised $60M+ of run-rate savings in 2027.
d) Capital return & balance sheet. IVZ is targeting a ~60% total payout ratio for 2026. Watch for accelerating buybacks (only $40M/1.6M shares in Q1, but a fresh $1B authorization was approved in February), the dividend (raised to $0.215), continued paydown of the ~$1.1B revolver balance, and any commentary on the remaining ~$3B of MassMutual preferred (they've already retired $1.5B). Deleveraging + EBITDA growth should improve leverage ratios through the year.
e) Portfolio actions. The CI Financial (Canada) partnership was set to close at end of Q2, transferring ~$19B AUM with a modest ~$5–10M/quarter operating-income drag in H2 (already in guidance). Management signaled the pruning (intelliflo, India JV stake) is largely done — confirm no new surprises.
f) Private markets & partnerships. Progress updates on the Barings and LGT Capital partnerships, INCREF (real-estate credit, ~$5B), the new DC-focused real estate CIT, and reassurance on private-credit quality (zero software/BDC exposure) are worth tracking as the higher-fee growth optionality.
IVZ is ~$30.1 (Jul 27), up ~11.8% YTD and ~32% off its April 7 low (~$22.77) — shares rallied sharply, including a jump in mid-July, and are pressing toward their YTD high right into the report. That means expectations have caught up somewhat. For context, IVZ has trailed Franklin (BEN, ~+40% YTD) but is broadly in line with T. Rowe (TROW, ~+14% YTD).
Bottom line: The quarter itself should look strong — record AUM, ~7% higher average AUM, a first full quarter of QQQ fees, and continued operating leverage all point to a clean sequential and YoY step-up. With the stock having already rerated, the swing factors are (1) QQQ flow/fee resilience against new competition, (2) confirmation that organic growth and margins are still inflecting higher, and (3) capital-return cadence. A reassuring message on QQQ plus visible margin progress toward the high-30s is what bulls need; any sign of QQQ flow leakage or fee pressure is the primary downside risk.
Note: I was unable to retrieve published sell-side consensus for the quarter, so the EPS/revenue figures above are my own model-based estimates and should be calibrated against the Street number you have.